During the last session, Quince Therapeutics Inc (NASDAQ:QNCX)’s traded shares were 2.18 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stock’s price was $1.62, reflecting an intraday gain of 23.66% or $0.31. The 52-week high for the QNCX share is $1.79, that puts it down -10.49 from that peak though still a striking 68.52% gain since the share price plummeted to a 52-week low of $0.51. The company’s market capitalization is $70.11M, and the average intraday trading volume over the past 10 days was 2.42 million shares, and the average trade volume was 489.29K shares over the past three months.
Quince Therapeutics Inc (NASDAQ:QNCX) trade information
Quince Therapeutics Inc (QNCX) registered a 23.66% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 23.66% in intraday trading to $1.62, hitting a weekly high. The stock’s 5-day price performance is 36.13%, and it has moved by 109.03% in 30 days. Based on these gigs, the overall price performance for the year is 66.91%. The short interest in Quince Therapeutics Inc (NASDAQ:QNCX) is 1.91 million shares and it means that shorts have 30.08 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.64%.
QNCX Dividends
Quince Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Quince Therapeutics Inc (NASDAQ:QNCX)’s Major holders
Quince Therapeutics Inc insiders own 13.74% of total outstanding shares while institutional holders control 25.24%, with the float percentage being 29.27%.
